Skip to main navigation Skip to search Skip to main content

Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice

  • Korean Multiple Myeloma Working Party
  • The Catholic University of Korea
  • National Cancer Center of Korea
  • Yonsei University
  • Seoul National University
  • Korea University
  • Chonnam National University
  • University of Ulsan
  • Gachon University

Research output: Contribution to journal › Article › peer-review

Abstract

Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56.3%. Three patients with creatinine clearance <30 ml/min even achieved an overall response. The median progression-free survival was 2.7 months with 28.9% (95% CI, 9.0–52.8) of 6-month progression-free survival. All infusion-related reactions, including ≥Grade 3 back pain (6.3%) and dyspnea (6.3%), were manageable. The most common hematologic and non-hematological adverse events were anemia (62.5%) and upper respiratory infection (43.8%). ≥Grade 3 bacterial infectious adverse events were identified, including upper and lower respiratory infection (12.5% and 18.8%) and death following sepsis (6.3%). We observed acceptable outcomes of daratumumab monotherapy on relapsed or refractory multiple myeloma patients including even a few subjects with high comorbidity, despite relatively frequent infectious adverse events.

Original languageEnglish
Pages (from-to)92-95
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume49
Issue number1
DOIs
StatePublished - 1 Jan 2019

Keywords

  • CD38
  • Daratumumab
  • Multiple myeloma
  • Refractory
  • Relapsed

Fingerprint

Dive into the research topics of 'Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice'. Together they form a unique fingerprint.

Cite this